Next Article in Journal
Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs
Previous Article in Journal
The Development of Sarcoidosis in an Ulcerative Colitis Patient Treated with Vedolizumab: A Case Report and Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Clinics and Practice
Volume 16
Issue 3
10.3390/clinpract16030045
clinpract-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Characteristics, Complications, Comorbidities, and Other Manifestations of Inflammatory Bowel Disease: A 7-Year Tertiary Center Experience

by
Waleed Alharbi
1,2,*,
Turki Alasmari
1,2,
Najla Al Rasheed
2,3,
Jamila A. Alonazi
2,3,
Naif K. Alaqil
1,2,*,
Meshari Al Samih
1,2,
Nawaf S. Alzahrani
1,2,
Abdulaziz Bin Akrish
2,3 and
Soliman Alaraidh
3,4
1
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia
2
King Abdullah International Medical Research Center, Riyadh 11481, Saudi Arabia
3
Department of Internal Medicine, King Abdulaziz Medical City Riyadh, Riyadh 11426, Saudi Arabia
4
Department of Family Medicine, King Abdulaziz Medical City Riyadh, Riyadh 11426, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Clin. Pract. 2026, 16(3), 45; https://doi.org/10.3390/clinpract16030045
Submission received: 15 November 2025 / Revised: 17 December 2025 / Accepted: 9 February 2026 / Published: 24 February 2026
Browse Figures
Versions Notes

Abstract

Background/Objectives: Inflammatory bowel disease (IBD) is associated with significant morbidity worldwide. While global epidemiological trends are well-documented, data on the clinical and demographic characteristics of IBD patients in Saudi Arabia remain limited. This study aimed to evaluate the distribution of multimorbidity among IBD patients in a tertiary Saudi hospital and assess associated clinical features and outcomes. Methods: A retrospective cross-sectional study of IBD patients treated at the National Guard Hospital over a seven-year period was conducted. Data on demographics, body mass indices (BMIs), hospitalizations, comorbidities, complications, and surgical interventions were extracted from medical records. Associations between categorical and continuous variables were analyzed using chi-square and t-tests, respectively, with significance being set to p < 0.05. Results: A total of 465 patients were included: 54.6% had Crohn’s disease (CD) and 45.4% had ulcerative colitis (UC). CD predominated in males (60.6%), while UC was more common in females (55.5%, p = 0.001). BMI distribution differed significantly between groups (p = 0.004). Hospital admission rates and length of stay were higher among CD patients (p = 0.032). CD patients experienced greater complication rates, including fistulas (41.3% vs. 7.1%, p < 0.001) and strictures (26.1% vs. 1.4%, p < 0.001). Surgical interventions such as fistulotomy (4.3% vs. 0.5%, p = 0.009) and stricturoplasty (9.1% vs. 1.9%, p = 0.001) were more frequent in patients with CD. Conclusions: This study characterizes IBD patients in Saudi Arabia, highlighting gender differences, BMI variations, and the greater severity of CD compared with UC. The higher rates of complications and surgical interventions among CD patients emphasize the need for tailored management strategies. Future prospective studies are warranted to investigate disease progression and optimize care for this population.

1. Introduction

Multimorbidity is defined as co-occurrence of at least two chronic conditions in the same individual [1]. Multimorbidity is a significant global issue that is constantly growing and impacting patients, caregivers, society, and health systems and resource poor settings in particular [2,3]. Multimorbidity is distinct from the similar concept of comorbidity, which refers to the combined effects of additional conditions in relation to the primary condition in an individual [4,5]. In contrast, multimorbidity care is patient-centered and does not habitually prioritize any particular ailment, while in clinical care, patients and doctors will normally focus on the patient’s most pressing difficulties.
In contrast to people with a single chronic condition, people with multimorbidity have a higher probability of dying prematurely, experience constant hospital admissions and have an increased length of stay [6,7]. Multimorbidity is also associated with poorer function and health-related quality of life (HRQoL), depression, intake of multiple drugs (polypharmacy), and greater socioeconomic costs [8,9,10]
Inflammatory bowel disease (IBD) is signalized by repeated episodes of inflammation of the gastrointestinal tract caused by an abnormal immune response to gut microflora [11]. IBD encompasses two idiopathic conditions that affect the intestines; they are differentiated by their depth, involvement of the bowel wall, character, and location of inflammation [12].
Ulcerative colitis (UC) involves disseminated inflammation of the colonic mucosa. Almost always, UC affects the rectum in the form of proctitis, but it can manifest in the sigmoid (proctosigmoiditis), beyond the sigmoid (distal ulcerative colitis), or include the entire colon up to the cecum (pancolitis) [13]. Crohn’s disease (CD) results in transmural ulceration of any part of the gastrointestinal tract (GI), most often affecting the terminal ileum and colon. Both diseases are classified by extent (mild, moderate, or severe) and location. CD is also classified by inflammatory phenotype, structuring, and penetration [14].
In the mid-1990s, Hudson and 6 colleagues were among the first to consider IBD as an independent factor for increased cardiovascular risk [15]. Along with an increased prevalence of nonalcoholic fatty liver disease (NAFLD), obesity, chronic fatigue, and erectile dysfunction have been shown in patients with IBD [16,17,18]. Another paper showcased how common comorbidities among IBD patients are, as 78% of IBD patients had at least one comorbidity, with a median of three comorbidities [19]. As this showcases the global burden on healthcare systems around the world, especially in Saudi Arabia, or even the greater Middle East, we lack literature that targets and showcases multimorbidity in this region.
It warrants further effort and investigation into the subject; therefore, we aim to study the prevalence of multimorbidity in IBD patients and illustrate the association between multimorbidity and IBD patient characteristics and care outcomes in a tertiary care center in Riyadh, Kingdom of Saudi Arabia.

2. Materials and Methods

A retrospective cross-sectional study was conducted at National Guard Health Affairs (NGHA) Hospitals in Saudi Arabia. NGHA is a well-established healthcare institution offering a broad spectrum of clinical, academic, and research services, ranging from public health and primary care to specialized tertiary care. This study aimed to analyze the clinical characteristics and disease patterns among patients diagnosed with inflammatory bowel disease (IBD). Data were collected through a systematic chart review using a structured data collection sheet. The study population included Saudi adolescents and adults diagnosed with IBD between January 2016 and September 2022. Patients aged between 15 and 70 years were included in the study, while those aged 14 years and younger were excluded.
The study included all adult patients (≥18 years) with a confirmed diagnosis of Crohn’s disease or ulcerative colitis established through clinical evaluation, endoscopic findings, and radiologic or histopathologic confirmation. Only patients who visited gastroenterology, internal medicine, and general surgery clinics between January 2016 and December 2024 and had complete medical records were eligible. Individuals with active or follow-up visits were included, provided their clinical, laboratory, and imaging data were available for analysis. Patients were excluded if they had an indeterminate or unconfirmed diagnosis of inflammatory bowel disease. Patients younger than 18 years or those who received care primarily at another institution with insufficient documentation were not included in the analysis.
The study utilized a non-probability consecutive sampling technique, as all eligible patients meeting the inclusion and exclusion criteria were included due to the limited number of subjects. Data were extracted from the Best Care system, an electronic medical records platform used at NGHA, to ensure the accuracy and completeness of the variables. The variables collected included demographic characteristics such as age, gender, and body mass index (BMI), as well as clinical variables such as type of IBD based on the Montreal IBD classification, history of thromboembolism, disease relapse and severity, family history of IBD, smoking status, extraintestinal manifestations, hospital readmissions, age at disease onset, inflammatory complications, presence of primary sclerosing cholangitis, and biologic medication usage. The data were collected from Best Care system over the period between 19 April 2024 and 3 August 2024. Comorbidities were identified and extracted using International Classification of Diseases (ICD-10) diagnostic codes recorded at the time of each patient’s clinic visit or hospitalization. For each patient, all active ICD-10 codes listed in problem lists and encounter diagnoses were reviewed.

3. Results

A total of 465 patients were included in the study, with 54.6% being diagnosed with Crohn’s disease (CD) and 45.4% with ulcerative colitis (UC). The mean age of the total sample was 38.40 years old with a standard deviation (SD) of 14.60 years. The gender distribution showed a slightly higher proportion of males (53.3%) than females (46.7%). The majority of patients were Saudi nationals (97.2%), while only 2.8% were non-Saudis. Regarding medication usage, the distributions of non-biological and biological treatments were nearly equal, with 49.6% receiving non-biological therapy and 50.4% receiving biological therapy. Hospital admission duration varied among patients, with 47.7% never being admitted, 8.8% being admitted for 1–3 days, 19.7% for 4–7 days, 13.5% for 8–14 days, 7.1% for 15 days to one month, and 3.4% for more than one month (Table 1).
Among the total cohort, 12.5% were classified as underweight, 35.3% as having a normal weight, 26.9% as overweight, and 25.4% as obese. This distribution highlights the significant variation in BMI among patients with inflammatory bowel disease (IBD) (Figure 1).
The data collected were managed and analyzed using Statistical Package for Social Sciences (SPSS) version 25. Prior to analysis, data cleaning and coding were performed to ensure consistency and accuracy. Descriptive statistics were used to summarize categorical variables as frequencies and percentages, while continuous variables were expressed as means with standard deviations. To compare means and proportions, Student’s t-test and chi-square (χ2) tests were employed, respectively. Additionally, multivariate logistic regression analysis was conducted to identify factors associated with disease outcomes, including variables that demonstrated statistical significance at the bivariate level. A p-value of less than 0.05 was considered statistically significant for all analyses.
Higher comorbidity burden was significantly associated with older age (p < 0.001). Female patients were more likely to have ≥3 comorbidities compared with males (p = 0.002), and the prevalence of obesity increased progressively with comorbidity burden (p = 0.006). Use of non-biological therapy was more frequent among patients with a higher number of comorbidities (p = 0.003). Patients with ≥3 comorbidities experienced significantly longer hospital stays (p = 0.017), and readmission rates differed significantly across comorbidity groups (p = 0.019). Nationality was not associated with comorbidity burden. Crohn’s disease was more common among patients with a single comorbidity, whereas ulcerative colitis predominated in those with ≥3 comorbidities (p = 0.029) (Table 2).
Anatomical involvement differed significantly by IBD type, with Crohn’s disease predominantly affecting the small intestine or presenting with combined intestinal involvement, whereas ulcerative colitis was largely confined to the large intestine (p < 0.001). Extra-intestinal anatomical involvement was more frequently observed in ulcerative colitis, particularly rectal involvement (p < 0.001). Metabolic comorbidities, including diabetes mellitus, hyperlipidemia, and hypertension, were significantly more prevalent among patients with ulcerative colitis compared with those with Crohn’s disease (p = 0.011, p < 0.001, and p = 0.004, respectively). Endocrine disorders, most notably hypothyroidism, were also more common in ulcerative colitis (p = 0.002). In addition, primary sclerosing cholangitis demonstrated a strong association with ulcerative colitis (p < 0.001). Smoking was significantly more prevalent among patients with Crohn’s disease (p = 0.007), whereas stroke occurred more frequently in patients with ulcerative colitis (p = 0.014) (Table 3).
The most common comorbidity among the patients was diabetes mellitus affecting 15.3% of the cohort. Other frequently reported conditions included anemia (13.80%), vitamin D deficiency (13.8%), and hyperlipidemia (12.0%). Hypertension was present in 9.9% of cases, followed by arthritis (11.2%) and psychiatric disorders (6.9%). Smoking was reported in 7.5% of patients. Autoimmune disorders such as psoriasis, celiac disease, and systemic lupus erythematosus (SLE) were uncommon, with respective prevalences of 2.8%, 1.7%, and 1.1% (Figure 2).
CD patients had a significantly higher prevalence of perianal fistulas (18.1%) compared to UC patients (4.3%) (p < 0.001). Similarly, hemorrhoids were more common among CD patients (16.1%) than UC patients (9.0%) (p = 0.022). Anal abscesses were also significantly more frequent in CD patients (4.7%) compared to UC patients (1.4%) (p = 0.045). However, there were no significant differences between the two groups regarding anal fissures and anal strictures (Table 4).
CD patients exhibited a significantly higher incidence of complications compared to UC patients. Fistulas were more prevalent among CD patients (41.3%) compared to UC patients (7.1%) (p < 0.001). Similarly, strictures were significantly more common in CD patients (26.1%) than in UC patients (1.4%) (p < 0.001). Abscesses and bowel obstruction were also more frequent in CD patients, with abscesses occurring in 10.6% of CD cases compared to 1.4% in UC (p < 0.001) and bowel obstruction affecting 6.3% of CD patients versus 0.5% of UC patients (p = 0.001). Perforations were observed in 3.9% of CD cases compared to 0.9% of UC cases (p = 0.043). No significant differences were noted for adhesions and polyps between the two groups (Table 5).
CD patients had significantly higher rates of fistulotomy (4.3% vs. 0.5%, p = 0.009) and stricturoplasty (9.1% vs. 1.9%, p = 0.001) compared to UC patients. Hemicolectomy was performed more frequently in UC patients (4.3%) than in CD patients (0.8%) (p = 0.014). Proctocolectomy was exclusively performed in CD patients (2.4%) but not in UC patients (p = 0.025). No significant differences were found in ileocecal resection, total colectomy, subtotal colectomy, small bowel resection, or abscess drainage between the two groups (Table 6).
The associations between comorbidities (diabetes, hyperlipidemia, hypertension, and pancreatitis due to therapy) and the type and duration of hospital admission were analyzed. The duration of the longest hospital admission varied based on the presence of comorbidities. Notably, patients without diabetes had a higher percentage of not being admitted (55.1%), whereas those with type 1 diabetes had a slightly higher percentage (58.6%). However, all patients with type 2 diabetes required hospitalization for at least four days. The differences in admission duration among diabetes groups were not statistically significant (p = 0.316). Similarly, no significant associations were found between admission duration and hyperlipidemia (p = 0.146), hypertension (p = 0.352), or pancreatitis due to therapy (p = 0.066).
Regarding surgical interventions, hemicolectomy and subtotal colectomy showed significant associations with diabetes (p < 0.001), while ileocecectomy was significantly associated with pancreatitis due to therapy (p = 0.001). Other surgical procedures, such as fistulotomy, stricturoplasty, abscess drainage, ileocecal resection, and small bowel resection, did not show significant associations with any of the analyzed comorbidities (Table 7).

4. Discussion

The present study provided a comprehensive analysis of the clinical and demographic characteristics of inflammatory bowel disease (IBD) patients over the past three decades at a single referral center in Saudi Arabia. Our findings highlighted important differences in disease patterns, comorbidities, and treatment modalities between Crohn’s disease (CD) and ulcerative colitis (UC) patients, reflecting broader trends observed in global epidemiological studies.
The predominance of CD (54.6%) over UC (45.4%) in our cohort aligned with some regional studies suggesting an increasing prevalence of CD in Middle Eastern populations [19,20]. This distribution contrasted with Western populations, where UC had traditionally been more prevalent than CD [21]. The gender distribution revealed a male predominance (53.3%), with significant differences between CD and UC patients. CD was more common in males (60.6%), whereas UC was more prevalent in females (55.5%). This gender-based variation was consistent with prior research indicating a higher prevalence of CD in men and UC in women in some populations, possibly due to hormonal, genetic, and environmental factors [22,23].
As per our findings, patients with ≥3 comorbidities had longer hospital stays (p = 0.017). However, readmission rates differed significantly across comorbidity groups (p = 0.019). As reported by prior literature, predictive factors of readmission for ulcerative colitis were younger age, male sex, and transfusion [24]. For Crohn’s disease, chronic pain and younger age were predictive factors for readmission [25,26].
Obesity increased with comorbidity burden (p = 0.006). Moreover, according to prior literature, obesity is a factor associated with increased early readmission with higher burden, with prevention of obesity being a cornerstone to decrease readmission and health care burden [27]. In contrast, obesity was equally distributed among both CD and UC patients, which is consistent with emerging evidence suggesting a rising prevalence of obesity in IBD populations due to lifestyle changes and corticosteroid use [28].
Hospital admission patterns varied significantly between CD and UC patients. A higher proportion of UC patients had never been hospitalized (63.0%) compared to CD patients (49.2%), whereas CD patients experienced more prolonged hospital stays, with 4.7% requiring admission for over a month. This aligned with studies indicating that CD is associated with more severe disease progression, requiring frequent hospitalizations and surgical interventions [29,30].
Regarding anatomical involvement, a substantial proportion of CD patients exhibited both small and large intestine involvement (52.8%), reflecting the characteristic nature of CD as a transmural disease. UC is confined to patient’s large intestine. Extra-intestinal involvement was relatively uncommon, with rectal involvement being the most frequently reported (17.0%), followed by stomach (3.4%) and esophageal involvement (1.3%). These findings were consistent with previous literature, which emphasizes the heterogeneity of IBD manifestations and the potential for extra-intestinal complications [29].
Comorbid conditions were prevalent, with anemia (26.5%) being the most common, followed by endocrine disorders (22.6%) and vitamin D deficiency (13.8%). Anemia is a well-documented complication of IBD that is often attributed to chronic inflammation, gastrointestinal bleeding, and micronutrient deficiencies [31]. Endocrine disorders, particularly vitamin D deficiency, have been frequently reported in IBD patients and are thought to be linked to disease activity and immune dysregulation [32]. Adding on that, IBD and Type 2 Diabetes Mellitus have been linked throughout many studies. Furthermore, some studies described the association to be linked with steroid use while others determined that there was a correlation regardless of steroid use [33,34], which shows that more light needs to be shed on the matter.
A significant finding in our study was the higher prevalence of perianal fistulas (18.1% vs. 4.3%, p < 0.001), strictures (26.1% vs. 1.4%, p < 0.001), and absences (10.6% vs. 1.4%, p < 0.001) in CD patients compared to UC patients. This is in accordance with prior studies highlighting the aggressive nature of CD, which often necessitates surgical interventions due to complications such as fistulas, strictures, and abscess formation [35]. Additionally, CD patients underwent significantly higher rates of stricturoplasty (9.1% vs. 1.9%, p = 0.001) and fistulotomy (4.3% vs. 0.5%, p = 0.009), reinforcing the need for surgical management in refractory cases [36].
These findings emphasize the need for a multidisciplinary approach in managing IBD patients with comorbidities, as metabolic disorders can influence disease outcomes and surgical risks.
This study has several strengths, including a large sample size and a long-term retrospective analysis. However, limitations such as single-center design and retrospective nature may impact generalizability. Future multicenter studies are needed to validate our findings and explore additional factors influencing IBD progression in the Saudi population.

5. Conclusions

In conclusion, our findings provide valuable insights into the clinical, comorbidity, and disease burden characteristics of IBD patients in Saudi Arabia. The higher prevalence of CD, its association with more severe complications, and the significant role of comorbidities highlight the need for comprehensive disease management strategies. Further research should focus on identifying risk factors contributing to disease severity and optimizing therapeutic approaches to improve patient outcomes.
Limitations:
While consecutive sampling and EMR extraction provide a practical and real-world overview of IBD patient characteristics, the findings should be interpreted in light of potential selection bias, missing data, and documentation variability inherent to retrospective designs.

Author Contributions

Conceptualization, W.A.; T.A.; N.K.A.; M.A.S.; N.S.A.; and A.B.A.; methodology, W.A.; T.A.; N.K.A.; M.A.S.; N.S.A.; and A.B.A.; software, M.A.S.; writing—original draft preparation, A.B.A. and S.A.; writing—review and editing, W.A.; N.A.R.; J.A.A.; and S.A.; supervision, N.A.R. and J.A.A.; project administration, N.A.R. and J.A.A.; investigation, W.A.; T.A.; N.K.A.; M.A.S.; and N.S.A.; visualization, A.B.A. and S.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of King Abdullah International Medical Research Center (IRB approval number: NRC23R/770/11) on 17 June 2025.

Informed Consent Statement

Patient consent was waived due to the retrospective nature and use of anonymized data.

Data Availability Statement

The original data presented in the study are openly available in FigShare at https://figshare.com/account/articles/30625409?file=59572733 (accessed on 7 November 2025).

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
IBDInflammatory Bowel Disease
CDCrohn’s Disease
UCUlcerative Colitis
BMIBody Mass Index
NGHANational Guard Health Affairs
PSCPrimary Sclerosing Cholangitis

References

  1. Australian Institute of Health and Welfare. Chronic Condition Multimorbidity 2021: What is Multimorbidity and How Common Is It? Australian Institute of Health and Welfare: Canberra, Australia, 2021. Available online: https://www.aihw.gov.au/reports/chronic-disease/chronic-condition-multimorbidity-2021 (accessed on 17 October 2023).
  2. Banerjee, A.; Hurst, J.; Fottrell, E.; Miranda, J.J. Multimorbidity: Not Just for the West. Glob. Heart. 2020, 15, 35694. [Google Scholar] [CrossRef] [PubMed]
  3. MacRae, C.; Morales, D.; Mercer, S.W.; Lone, N.; Lawson, A.; Jefferson, E.; McAllister, D.; Akker, M.v.D.; Marshall, A.; Seth, S.; et al. Impact of Data Source Choice on Multimorbidity measurement: A Comparison Study of 2.3 Million Individuals in the Welsh National Health Service. BMC Med. 2023, 21, 309. Available online: https://pubmed.ncbi.nlm.nih.gov/37582755/#:~:text=Results%3A%20Using%20linked%20PC%2DHI (accessed on 17 October 2023). [CrossRef]
  4. Nicholson, K.; Almirall, J.; Fortin, M. The measurement of multimorbidity. Health Psychol. 2019, 38, 783–790. [Google Scholar] [CrossRef] [PubMed]
  5. Harrison, C.; Fortin, M.; Akker, M.v.D.; Mair, F.; Calderon-Larranaga, A.; Boland, F.; Wallace, E.; Jani, B.; Smith, S. Comorbidity versus multimorbidity: Why it matters. J. Multimorb. Comorbidity 2021, 11, 3993. [Google Scholar] [CrossRef]
  6. Breen, K.; Finnegan, L.; Vuckovic, K.; Fink, A.; Rosamond, W.; DeVon, H.A. Multimorbidity in Patients with Acute Coronary Syndrome Is Associated with Greater Mortality, Higher Readmission Rates, and Increased Length of Stay. J. Cardiovasc. Nurs. 2020, 35, E99–E110. [Google Scholar] [CrossRef]
  7. Rodrigues, L.P.; de Oliveira Rezende, A.T.; Delpino, F.M.; Mendonça, C.R.; Noll, M.; Nunes, B.P.; De Oliviera, C.; Silveira, E.A. Association between multimorbidity and hospitalization in older adults: Systematic review and meta-analysis. Age Ageing 2022, 51, afac155. [Google Scholar] [CrossRef]
  8. Van Wilder, L.; Devleesschauwer, B.; Clays, E.; Pype, P.; Vandepitte, S.; De Smedt, D. Polypharmacy and health-related quality of life/psychological distress among patients with chronic disease. Prev. Chronic Dis. 2022, 19, E50. Available online: https://www.cdc.gov/pcd/issues/2022/22_0062.htm (accessed on 17 October 2023).
  9. Chang, C.K.; Chen, Y.C.; Chou, Y.J.; Chou, P. Multimorbidity patterns and their association with depression: A population-based study. Healthcare 2025, 13, 1458. Available online: https://www.mdpi.com/2227-9032/13/12/1458 (accessed on 18 October 2023).
  10. Tran, P.B.; Kazibwe, J.; Nikolaidis, G.F.; Linnosmaa, I.; Rijken, M.; van Olmen, J. Costs of multimorbidity: A systematic review and meta-analyses. BMC Med. 2022, 20, 234. Available online: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02427-9 (accessed on 18 October 2023). [CrossRef]
  11. McDowell, C.; Farooq, U.; Haseeb, M. Inflammatory Bowel Disease. 2025. Available online: http://www.ncbi.nlm.nih.gov/pubmed/30137275 (accessed on 18 October 2023).
  12. Maaser, C.; Sturm, A.; Vavricka, S.R.; Kucharzik, T.; Fiorino, G.; Annese, V.; Calabrese, E.; Baumgart, D.C.; Bettenworth, D.; Borralho Nunes, P.; et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohn’s Colitis. 2019, 13, 144–164. [Google Scholar] [CrossRef]
  13. Dmochowska, N.; Wardill, H.R.; Hughes, P.A. Advances in Imaging Specific Mediators of Inflammatory Bowel Disease. Int. J. Mol. Sci. 2018, 19, 2471. [Google Scholar] [CrossRef] [PubMed]
  14. Colombel, J.-F.; Shin, A.; Gibson, P.R. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease: Expert Review. Clin. Gastroenterol. Hepatol. 2019, 17, 380–390. [Google Scholar] [CrossRef]
  15. Hudson, M.; Chitolie, A.; Hutton, R.A.; Smith, M.S.; Pounder, R.E.; Wakefield, A.J. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996, 38, 733–737. [Google Scholar] [CrossRef]
  16. Chalasani, N.; Younossi, Z.; LaVine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [Google Scholar] [CrossRef]
  17. Friedman, S.; Magnussen, B.; O’Toole, A.; Fedder, J.; Larsen, M.D.; Nørgård, B.M. Increased Use of Medications for Erectile Dysfunction in Men with Ulcerative Colitis and Crohn’s Disease Compared to Men Without Inflammatory Bowel disease: A Nationwide cohort Study. Am. J. Gastroenterol. 2018, 113, 1355. [Google Scholar] [CrossRef] [PubMed]
  18. D’Silva, A.; Fox, D.E.; Nasser, Y.; Vallance, J.K.; Quinn, R.R.; Ronksley, P.E.; Raman, M. Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: A systematic review with meta-analysis. Clin. Gastroenterol. Hepatol. 2022, 20, 995–1009. [Google Scholar] [CrossRef] [PubMed]
  19. Al-Fawzan, A.A.; Al-Radhi, S.A.; Al-Omar, A.S.; Al-Mutiri, N.H.; Al-Ammari, A.M.; El-Gohary, M.; Shamsan, A.N.; Al Shehri, H.M.; Alghasab, N.S. A Study of the Epidemiology, Clinical, and Phenotypic Characteristics of Inflammatory Bowel Disease in the Northen-Central Region of Saudi Arabia. Diagnostics 2023, 13, 2135. [Google Scholar] [CrossRef]
  20. Burisch, J. Crohn’s disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan. Med. J. 2014, 61, B4778. Available online: http://www.ncbi.nlm.nih.gov/pubmed/24393595 (accessed on 14 November 2025). [PubMed]
  21. Weisman, M.H.; Stens, O.; Kim, H.S.; Hou, J.K.; Miller, F.W.; Dillon, C.F. Inflammatory Bowel Disease Prevalence: Surveillance data from the U.S. National Health and Nutrition Examination Survey. Prev. Med. Reports. 2023, 33, 102173. [Google Scholar] [CrossRef]
  22. Rustgi, S.D.; Kayal, M.; Shah, S.C. Sex-based differences in inflammatory bowel diseases: A review. Therap. Adv. Gastroenterol. 2020, 13, 15043. [Google Scholar] [CrossRef]
  23. Massironi, S.; Viganò, C.; Palermo, A.; Pirola, L.; Mulinacci, G.; Allocca, M.; Peyrin-Biroulet, L.; Danese, S. Inflammation and malnutrition in inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 2023, 8, 579–590. [Google Scholar] [CrossRef]
  24. Kunkle, B.; Singh, H.; Abraham, D.; Asamoah, N.; Barrow, J.; Mattar, M. Independent predictors of 90-day readmission in patients with inflammatory bowel disease: A nationwide retrospective study. J. Crohns Colitis 2025, 19, jjaf034. [Google Scholar] [CrossRef] [PubMed]
  25. Barnes, E.L.; Kochar, B.; Long, M.D.; Kappelman, M.D.; Martin, C.F.; Korzenik, J.R.; Crockett, S.D. Modifiable risk factors for hospital readmission among patients with inflammatory bowel disease: A nationwide analysis. Inflamm. Bowel Dis. 2017, 23, 1332–1340. [Google Scholar] [CrossRef]
  26. Ghahramani, S.; Tamartash, Z.; Sayari, M.; Vahedi, H.; Karimian, F.; Heydari, S.; Lankarani, K.B. Risk factors affecting 90-day readmission of patients with inflammatory bowel disease. Middle East J. Dig. Dis. 2022, 14, 34–43. [Google Scholar] [CrossRef] [PubMed]
  27. Kaazan, P.; Seow, W.; Yong, S.; Heilbronn, L.K.; Segal, J.P. The Impact of Obesity on Inflammatory Bowel Disease. Biomedicines 2023, 11, 3256. [Google Scholar] [CrossRef]
  28. Weissman, S.; Patel, K.; Kolli, S.; Lipcsey, M.; Qureshi, N.; Elias, S.; Walfish, A.; Swaminath, A.; Feuerstein, J.D. Obesity in Inflammatory Bowel Disease Is Associated with Early Readmissions Characterised by an Increased Systems and Patient-level Burden. J. Crohn’s Colitis 2021, 16, 1807–1815. [Google Scholar] [CrossRef]
  29. Tsai, L.; Nguyen, N.H.; Ma, C.; Prokop, L.J.; Sandborn, W.J.; Singh, S. Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn’s Disease in Population-Based Cohort Studies. Dig. Dis. Sci. 2022, 67, 2451–2461. [Google Scholar] [CrossRef]
  30. Niv, Y. Hospitalisation of patients with Crohn’s disease: A systematic review and meta-analysis. Isr. Med. Assoc. J. 2020, 22, 111–115. [Google Scholar] [CrossRef]
  31. Mahadea, D.; Adamczewska, E.; Ratajczak, A.E.; Rychter, A.M.; Zawada, A.; Eder, P.; Dobrowolska, A.; Krela-Kaźmierczak, I. Iron Deficiency Anemia in Inflammatory Bowel Diseases—A Narrative Review. Nutrients 2021, 13, 4008. [Google Scholar] [CrossRef]
  32. Vernia, F.; Valvano, M.; Longo, S.; Cesaro, N.; Viscido, A.; Latella, G. Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications. Nutrients 2022, 14, 269. [Google Scholar] [CrossRef]
  33. Sang, M.M.; Sun, Z.L.; Wu, T.Z. Inflammatory bowel disease and diabetes: Is there a link between them? World J. Diabetes. 2022, 13, 126–128. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  34. Kang, E.A.; Han, K.; Chun, J.; Soh, H.; Park, S.; Im, J.P.; Kim, J.S. Increased Risk of Diabetes in Inflammatory Bowel Disease Patients: A Nationwide Population-based Study in Korea. J. Clin. Med. 2019, 8, 343. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  35. Singh, S.; Picardo, S.; Seow, C.H. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clin. Gastroenterol. Hepatol. 2020, 18, 1367–1380. [Google Scholar] [CrossRef] [PubMed]
  36. Jiang, K.; Chen, B.; Lou, D.; Zhang, M.; Shi, Y.; Dai, W.; Shen, J.; Zhou, B.; Hu, J. Systematic review and meta-analysis: Association between obesity/overweight and surgical complications in IBD. Int. J. Colorectal Dis. 2022, 37, 1485–1496. [Google Scholar] [CrossRef] [PubMed]
Clinpract 16 00045 g001
Figure 1. Distribution of patients according to their BMI. Percentages may not sum to exactly 100% due to rounding to one decimal place.
Figure 1. Distribution of patients according to their BMI. Percentages may not sum to exactly 100% due to rounding to one decimal place.
Clinpract 16 00045 g001
Clinpract 16 00045 g002
Figure 2. Frequency of comorbidities.
Figure 2. Frequency of comorbidities.
Clinpract 16 00045 g002
Table 1. Baseline characteristics of the study population (N = 465).
Table 1. Baseline characteristics of the study population (N = 465).
Frequency
N (%)
GenderFemale217 (46.7)
Male248 (53.3)
Age (Years)Mean (SD)38.4 (14.6)
BMIUnderweight58 (12.5)
Normal weight164 (35.3)
Overweight125 (26.9)
Obese118 (25.4)
NationalitySaudi452 (97.2)
Non-Saudi13 (2.8)
Medication TypeNon-biological230 (49.6)
Biological234 (50.4)
Duration of Longest AdmissionNot admitted222 (47.7)
1–3 days41 (8.8)
4–7 days90 (19.4)
8–14 days63 (13.5)
15 days–1 month33 (7.1)
>1 month16 (3.4)
DiagnosisCrohn’s disease (CD)254 (54.6)
Ulcerative colitis (UC)211 (45.4)
Table 2. Demographic and clinical characteristics of IBD patients stratified by comorbidity burden.
Table 2. Demographic and clinical characteristics of IBD patients stratified by comorbidity burden.
Comorbidities in IBD PatientsSig. Value
Patients with 1 Comorbidity
N (%)		Patients with 2 Comorbidities
N (%)		Patients with ≥3 Comorbidities
N (%)
GenderFemale51 (41.5)32 (39.0)77 (60.6)0.002
Male72 (58.5)50 (61.0)50 (39.4)
Age (Years)Mean (SD)32.6 (10.7)38.8 (13.3)49.3 (16.4)<0.001
BMIUnderweight21 (17.1)11 (13.4)9 (7.1)0.006
Normal weight45 (36.6)29 (35.4)38 (29.9)
Overweight32 (26.0)26 (31.7)30 (23.6)
Obese25 (20.3)16 (19.5)50 (39.4)
NationalitySaudi117 (95.1)81 (98.8)125 (98.4)0.173
Non-Saudi6 (4.9)1 (1.2)2 (1.6)
Medication TypeNon-biological51 (41.5)43 (52.4)80 (63.0)0.003
Biological72 (58.5)39 (47.6)47 (37.0)
Longest Admission DurationNot admitted56 (45.5)45 (54.9)70 (55.1)0.017
1–3 days8 (6.5)13 (15.9)7 (5.5)
4–7 days32 (26.0)8 (9.8)17 (13.4)
8–14 days15 (12.2)10 (12.2)14 (11.0)
15 days–1 month9 (7.3)3 (3.7)13 (10.2)
>1 month3 (2.4)3 (3.7)6 (4.7)
ReadmissionNo80 (65.0)67 (81.7)97 (76.4)0.019
Yes43 (35.0)15 (18.3)30 (23.6)
ConditionCD72 (58.5)40 (48.8)53 (41.7)0.029
UC51 (41.5)42 (51.2)74 (58.3)
Table 3. Association of clinical characteristics and comorbidities with IBD types among patients.
Table 3. Association of clinical characteristics and comorbidities with IBD types among patients.
Type of IBDSig. Value
CD
N (%)		UC
N (%)		Total
N (%)
Anatomical involvementNo data7 (2.8)15 (7.1)23 (4.9)<0.001
Small intestine55 (21.7)12 (5.7)67 (14.4)
Large intestine22 (8.7)139 (65.9)161 (34.6)
Both134 (52.8)14 (6.6)148 (31.8)
Unspecified36 (14.2)30 (14.2)66 (14.2)
Extra-intestinal anatomical involvementNone212 (83.5)142 (67.3)354 (76.1)<0.001
Esophagus4 (1.6)2 (0.9)6 (1.3)
Stomach8 (3.1)8 (3.8)16 (3.4)
Rectum22 (8.7)57 (27.0)79 (17.0)
Oral8 (3.1)2 (0.9)10 (2.2)
Extra-GI manifestationsNone228 (89.8)184 (87.2)412 (89.2)0.110
Hepatobiliary3 (1.2)12 (5.7)15 (3.3)
Ocular2 (0.8)2 (0.9)4 (0.9)
Skin4 (1.6)1 (0.5)5 (1.1)
MSK11 (4.3)7 (3.3)18 (3.1)
Others7 (2.75)3 (1.4)10 (2.2)
GI InfectionNone227 (89.4)181 (85.8)408 (87.7)0.483
H. pylori6 (2.4)3 (1.4)9 (1.94)
C. difficile15 (5.9)16 (7.6)31 (6.7)
Tuberculosis3 (1.2)2 (0.9)5 (1.1)
CMV2 (0.8)6 (2.8)8 (1.7)
Salmonella1 (0.4)1 (0.5)2 (0.4)
C. perfringens0 (0.0)1 (0.5)1 (0.2)
Brucellosis0 (0.0)1 (0.5)1 (0.2)
Renal diseaseNone248 (97.6)199 (94.3)447 (96.1)0.142
CKD6 (2.4)11 (5.2)17 (3.7)
Nephrotic0 (0.0)1 (0.5)1 (0.2)
ArthritisNo229 (90.2)184 (87.2)413 (88.8)0.314
Yes25 (9.8)27 (12.8)52 (11.2)
DiabetesNo225 (88.6)169 (80.1)394 (84.7)0.011
Yes29 (11.4)42 (19.9)71 (15.3)
Endocrine disordersNone246 (96.9)186 (88.2)432 (93.1)0.002
Hypothyroidism6 (2.4)20 (9.5)26 (5.6)
Hyperthyroidism2 (0.8)4 (1.9)6 (1.3)
HyperlipidemiaNo240 (94.5)169 (80.1)409 (88.0)<0.001
Yes14 (5.5)42 (19.9)56 (12.0)
HypertensionNo238 (93.7)181 (85.8)419 (90.1)0.004
Yes16 (6.3)30 (14.2)46 (9.9)
AnemiaNo193 (76.0)149 (70.6)342 (73.55)0.191
Yes61 (24.0)62 (29.4)123 (26.45)
Vitamin D deficiencyNo219 (86.2)182 (86.3)401 (86.24)0.991
Yes35 (13.8)29 (13.7)64 (13.76)
Vitamin B12 deficiencyNo248 (97.6)205 (97.2)453 (97.42)0.744
Yes6 (2.4)6 (2.8)12 (2.58)
Primary sclerosing cholangitisNo251 (98.8)187 (88.6)438 (94.19)<0.001
Yes3 (1.2)24 (11.4)27 (5.81)
SmokingNo222 (87.4)199 (94.3)425 (91.4)0.007
Yes26 (10.2)8 (3.8)40 (8.6)
Autoimmune diseasesNo248 (97.6)204 (96.7)452 (97.20)0.507
Psoriasis4 (1.6)4 (1.9)8 (1.72)
Celiac disease1 (0.4)3 (1.4)4 (0.86)
SLE1 (0.4)0 (0.0)1 (0.22)
StrokeNo252 (99.2)202 (95.7)454 (97.63)0.014
Yes2 (0.8)9 (4.3)11 (2.37)
Psychiatric disordersNo237 (93.3)196 (92.9)433 (93.12)0.860
Yes17 (6.7)15 (7.1)32 (6.88)
Table 4. Differences between CD and UC patients considering Hemorrhoid and perianal conditions.
Table 4. Differences between CD and UC patients considering Hemorrhoid and perianal conditions.
Diagnosis
CDUCp-Value
CountColumn
N %		CountColumn
N %
Perianal FistulaNo20881.9%20295.7%<0.001
Yes4618.1%94.3%
HemorrhoidNo21383.9%19291.0%0.022
Yes4116.1%199.0%
Anal FissureNo24998.0%20898.6%0.652
Yes52.0%31.4%
Anal AbscessNo24295.3%20898.6%0.045
Yes124.7%31.4%
Anal strictureNo25299.2%21099.5%0.674
Yes20.8%10.5%
Table 5. Association of perianal conditions, complications, and surgical procedures with IBD subtype (Crohn’s disease vs. ulcerative colitis).
Table 5. Association of perianal conditions, complications, and surgical procedures with IBD subtype (Crohn’s disease vs. ulcerative colitis).
IBD TypesSig.
Values
CD
N (%)		UC
N (%)
Hemorrhoid and Perianal Conditions
Perianal FistulaNo208 (81.9)202 (95.7)<0.001
Yes46 (18.1)9 (4.3)
HemorrhoidNo213 (83.9)192 (91.0)0.022
Yes41 (16.1)19 (9.0)
Anal FissureNo249 (98.0)208 (98.6)0.652
Yes5 (2.0)3 (1.4)
Anal AbscessNo242 (95.3)208 (98.6)0.045
Yes12 (4.7)3 (1.4)
Anal StrictureNo252 (99.2)210 (99.5)0.674
Yes2 (0.8)1 (0.5)
Different Complications
FistulaNo149 (58.7)196 (92.9)<0.001
Yes105 (41.3)15 (7.1)
StricturesNo187 (73.9)208 (98.6)<0.001
Yes66 (26.1)3 (1.4)
AdhesionsNo251 (98.8)211 (100.0)0.113
Yes3 (1.2)0 (0.0)
PerforationNo244 (96.1)209 (99.1)0.043
Yes10 (3.9)2 (0.9)
AbscessNo227 (89.4)208 (98.6)<0.001
Yes27 (10.6)3 (1.4)
PolypsNo247 (97.2)202 (95.7)0.374
Yes7 (2.8)9 (4.3)
Bowel obstructionNo238 (93.7)210 (99.5)0.001
Yes16 (6.3)1 (0.5)
Different Types of Surgeries
FistulotomyNo243 (95.7)210 (99.5)0.009
Yes11 (4.3)1 (0.5)
StricturoplastyNo231 (90.9)207 (98.1)0.001
Yes23 (9.1)4 (1.9)
Abscess drainageNo240 (94.5)206 (97.6)0.088
Yes14 (5.5)5 (2.4)
Ileocecal resectionNo253 (99.6)209 (99.1)0.457
Yes1 (0.4)2 (0.9)
HemicolectomyNo252 (99.2)202 (95.7)0.014
Yes2 (0.8)9 (4.3)
ProctocolectomyNo248 (97.6)211 (100.0)0.025
Yes6 (2.4)0 (0.0)
Total colectomyNo246 (96.9)209 (99.1)0.103
Yes8 (3.1)2 (0.9)
Subtotal colectomyNo245 (96.5)206 (97.6)0.461
Yes9 (3.5)5 (2.4)
Small bowel resectionNo245 (96.5)208 (98.6)0.151
Yes9 (3.5)3 (1.4)
IleocecectomyNo246 (97.2)209 (99.1)0.157
Yes7 (2.8)2 (0.9)
Table 6. Difference between CD and UC patients considering the type of surgery.
Table 6. Difference between CD and UC patients considering the type of surgery.
Diagnosis
CDUCp-Value
CountColumn
N %		CountColumn
N %
FistulotomyNo24395.7%21099.5%0.009
Yes114.3%10.5%
StricturoplastyNo23190.9%20798.1%0.001
Yes239.1%41.9%
Abscess drainageNo24094.5%20697.6%0.088
Yes145.5%52.4%
Ileocecal resectionNo25399.6%20999.1%0.457
Yes10.4%20.9%
HemicolectomyNo25299.2%20295.7%0.014
Yes20.8%94.3%
ProctocolectomyNo24897.6%211100.0%0.025
Yes62.4%00.0%
Total colectomyNo24696.9%20999.1%0.103
Yes83.1%20.9%
Subtotal colectomyNo24596.5%20697.6%0.461
Yes93.5%52.4%
Small bowl resectionNo24596.5%20898.6%0.151
Yes93.5%31.4%
IleocecectomyNo24697.2%20999.1%0.157
Yes72.8%20.9%
Table 7. Associations of different comorbidities with admission duration and surgical procedures.
Table 7. Associations of different comorbidities with admission duration and surgical procedures.
Duration of Longest AdmissionDiabetesHyperlipidemiaHypertensionPancreatitis due to Therapy
Duration of Longest AdmissionNot admitted217 (55.1)218 (53.3)226 (53.9)257 (55.7)
1–3 days30 (7.6)30 (7.3)33 (7.9)34 (7.4)
4–7 days68 (17.3)71 (17.4)71 (16.9)75 (16.3)
8–14 days47 (11.9)50 (12.2)50 (11.9)53 (11.5)
15 days–1 month20 (5.1)27 (6.6)26 (6.2)28 (6.1)
>1 month12 (3.0)13 (3.2)13 (3.1)14 (3.0)
p-value0.3160.1460.3520.066
FistulotomyYes25 (6.3)24 (5.9)25 (6.0)26 (5.6)
p-value0.9750.6180.4260.744
StricturoplastyYes18 (4.6)18 (4.4)19 (4.5)19 (4.1)
p-value0.5010.8780.6560.099
Abscess drainageYes2 (0.5)3 (0.7)2 (0.5)3 (0.7)
p-value0.4630.3540.1400.678
Ileocecal resectionYes7 (1.8)10 (2.4)11 (2.6)11 (2.4)
p-value0.6730.5200.1720.871
HemicolectomyYes6 (1.5)6 (1.5)6 (1.4)6 (1.3)
p-value<0.0010.7610.2660.755
Proctocolectomy Yes6 (1.5)6 (1.5)6 (1.4)6 (1.3)
p-value0.5780.3620.4140.818
Total colectomy Yes8 (2.0)10 (2.4)9 (2.1)10 (2.2)
p-value0.8980.2370.9910.766
Subtotal colectomyYes10 (2.5)14 (3.4)13 (3.1)14 (3.0)
p-value<0.0010.1600.7260.723
Small bowel resectionYes12 (3.0)12 (2.9)12 (2.9)12 (2.6)
p-value0.3300.1940.2450.744
IleocecectomyYes6 (1.5)9 (2.2)7 (1.7)8 (1.7)
p-value0.2890.2620.2120.001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Alharbi, W.; Alasmari, T.; Rasheed, N.A.; Alonazi, J.A.; Alaqil, N.K.; Al Samih, M.; Alzahrani, N.S.; Bin Akrish, A.; Alaraidh, S. Characteristics, Complications, Comorbidities, and Other Manifestations of Inflammatory Bowel Disease: A 7-Year Tertiary Center Experience. Clin. Pract. 2026, 16, 45. https://doi.org/10.3390/clinpract16030045

AMA Style

Alharbi W, Alasmari T, Rasheed NA, Alonazi JA, Alaqil NK, Al Samih M, Alzahrani NS, Bin Akrish A, Alaraidh S. Characteristics, Complications, Comorbidities, and Other Manifestations of Inflammatory Bowel Disease: A 7-Year Tertiary Center Experience. Clinics and Practice. 2026; 16(3):45. https://doi.org/10.3390/clinpract16030045

Chicago/Turabian Style

Alharbi, Waleed, Turki Alasmari, Najla Al Rasheed, Jamila A. Alonazi, Naif K. Alaqil, Meshari Al Samih, Nawaf S. Alzahrani, Abdulaziz Bin Akrish, and Soliman Alaraidh. 2026. "Characteristics, Complications, Comorbidities, and Other Manifestations of Inflammatory Bowel Disease: A 7-Year Tertiary Center Experience" Clinics and Practice 16, no. 3: 45. https://doi.org/10.3390/clinpract16030045

APA Style

Alharbi, W., Alasmari, T., Rasheed, N. A., Alonazi, J. A., Alaqil, N. K., Al Samih, M., Alzahrani, N. S., Bin Akrish, A., & Alaraidh, S. (2026). Characteristics, Complications, Comorbidities, and Other Manifestations of Inflammatory Bowel Disease: A 7-Year Tertiary Center Experience. Clinics and Practice, 16(3), 45. https://doi.org/10.3390/clinpract16030045

Article Metrics

Back to TopTop